Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REPLIGEN CORPORATION

(RGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Repligen Corporation : Underpinned by a support level

05/07/2021 | 02:43am EDT
long trade
Stop-loss triggered
Entry price : 186.46$ | Target : 226$ | Stop-loss : 175$ | Potential : 21.21%
The technical support around 178.78 USD emanating from daily closing prices could trigger a technical rebound for Repligen Corporation shares.
Investors have an opportunity to buy the stock and target the $ 226.
Repligen Corporation : Repligen Corporation : Underpinned by a support level
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has solid fundamentals for a short-term investment strategy.

Strengths
  • Share prices are approaching a strong support area in daily data, which offers good timing for investors.
  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The group's high margin levels account for strong profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • The group usually releases upbeat results with huge surprise rates.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Over the last seven days, analysts have been revising upwards their EPS estimates for the company.
  • For the past twelve months, EPS forecast has been revised upwards.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The stock is in a well-established, long-term rising trend above the technical support level at 166.57 USD

Weaknesses
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • With an expected P/E ratio at 115.22 and 101.35 respectively for both the current and next fiscal years, the company operates with high earnings multiples.

ę MarketScreener.com 2021

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2021 586 M - -
Net income 2021 97,5 M - -
Net cash 2021 596 M - -
P/E ratio 2021 113x
Yield 2021 -
Capitalization 10 589 M 10 589 M -
EV / Sales 2021 17,1x
EV / Sales 2022 14,3x
Nbr of Employees -
Free-Float 93,0%
Upcoming event on REPLIGEN CORPORATION
08/05/21
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 192,87 $
Average target price 240,25 $
Spread / Average Target 24,6%
EPS Revisions
Managers and Directors
Tony J. Hunt President, Chief Executive Officer & Director
Jon K. Snodgres Chief Financial Officer
Karen T. Dawes Chairman
Ralf Kuriyel Senior Vice President-Research & Development
James R. Bylund Senior Vice President-Global Operations & IT
Sector and Competitors
1st jan.Capitalization (M$)
REPLIGEN CORPORATION0.67%10 589
ABBOTT LABORATORIES2.02%196 943
MEDTRONIC PLC6.79%168 834
BECTON, DICKINSON AND COMPANY-4.16%69 860
HOYA CORPORATION5.01%49 973
ALIGN TECHNOLOGY, INC.15.53%48 858